DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.
Qué cambió
The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.
Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.
Por qué importa
Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.
Qué observar
La señal útil no es solo la cifra del titular, sino si el producto, contrato o giro de plataforma se repite en los próximos dos trimestres.
Fuentes: CocoLoop